Treatment restores some function in animal models of spinal muscular atrophy

October 14, 2015

In work involving several new generations of mouse model development, Jackson Laboratory (JAX) researchers have tested a therapeutic intervention for spinal muscular atrophy (SMA) that restores some function lost due to a mutation in one gene (SMN1) and amplifies the levels of protective genes (SMN2).

Moreover, unlike current interventions, the therapy appears to work after symptoms of SMA have already appeared, and may not need to be administered directly into the central nervous system.

SMA is a neurodegenerative disorder caused by mutations that cause loss of function in the Survival Motor Neuron (SMN) 1 gene. SMN1, as its name implies, is vital for proper motor neuron function and maintenance. SMA patients have varying levels of severity because of the presence of a homolog gene, SMN2, in humans. SMN2 provides some protection because a small number of the proteins produced from it function like SMN1. As a result, SMA disease prognosis depends on how many copies of SMN2 are present. Two or fewer copies of SMN2 leads to earlier onset, more severe disease, while three or more copies provide enough function to result in a later onset, milder form of SMA.

SMA has proven to be difficult to model in mice. Current mouse models expressing small amounts of SMN protein die very early, by about two weeks of age. Yet, increasing this protein level by just a small amount renders the mice almost normal. This makes therapy testing very difficult and doesn't model the symptoms or processes associated with the less severe types of the disease.

A research group led by Cat Lutz, Ph.D., director of the JAX Rare and Orpan Disease Center, is working to improve the ability to model SMA in mice. As published on October 12 in the Proceedings of the National Academy of Sciences, their first step was to genetically engineer mouse models with increasing copy numbers of human SMN2. Through this work they were able to develop a mouse model with very mild neuromuscular defects that lives a near normal life span, and little motor neuron denervation. So a better model was still needed.

The researchers developed a model with SMN1, human SMN2 and a third allele (dubbed the C allele) that combines parts of mouse SMN with parts of human SMN2. This combination produced a mouse that had a relatively long life span compared to severe mutants (about 100 days) combined with SMA-like neuromuscular disease phenotype.

The new model, called "Burgheron" to honor the researchers who made the integrated alleles available, allowed Lutz and her colleagues to test a current that restores SMN levels and has a significant effect in severe models. The therapy, known as an antisense oligonucleotide, worked to restore SMN levels in the Burgheron too, and even injections 25 days after symptoms had begun increased and restored motor unit function in the muscles.

"The majority of the preclinical data that we have to date comes from type I animal models and suggests that early intervention in the treatment of SMA is necessary," says Lutz. "However, we really don't have good preclinical data that supports whether this is also true for type II/III patients, who represent the majority of patients living with SMA. Our data indicate that post-symptomatic treatment, well into the disease state in mice, has a clinically relevant therapeutic benefit."

Human trials for therapeutics involving antisense oligonucleotides are delivered directly into the central nervous system (CNS). Peripheral application in the had benefits here, even at the neuromuscular junction, raising the question of what might be alternative delivery mechanisms in humans.

"The benefit may not be restricted to CNS delivery," says Lutz, "which opens up a whole new potential class of compounds and possibilities for combination therapies. Further study in humans will be needed, but the prospect of non-CNS delivery is of significant potential benefit for patients."

Explore further: Mechanistic insights into spinal muscular atrophy suggest new paths for treatment

More information: Laurent P. Bogdanik et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy, Proceedings of the National Academy of Sciences (2015). DOI: 10.1073/pnas.1509758112

Related Stories

Mechanistic insights into spinal muscular atrophy suggest new paths for treatment

January 12, 2015
Today, a team of researchers from Cold Spring Harbor Laboratory (CSHL) sheds new light on the underlying pathology of spinal muscular atrophy (SMA), a rare but devastating disease that causes muscle weakness and paralysis ...

Orally delivered compounds selectively modify RNA splicing, prevent deficits in SMA models

August 7, 2014
Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in a mouse model ...

First animal model of adult-onset SMA sheds light on disease progression, treatment

September 9, 2013
A research team at Cold Spring Harbor Laboratory (CSHL) has used a recently developed technology they call TSUNAMI to create the first animal model of the adult-onset version of spinal muscular atrophy (SMA), a devastating ...

Low oxygen levels may decrease life-saving protein in spinal muscular atrophy

August 21, 2012
Investigators at Nationwide Children's Hospital may have discovered a biological explanation for why low levels of oxygen advance spinal muscular atrophy (SMA) symptoms and why breathing treatments help SMA patients live ...

Gene therapy extends survival in an animal model of spinal muscular atrophy

May 22, 2014
To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords ...

Recommended for you

How defeating THOR could bring a hammer down on cancer

December 14, 2017
It turns out Thor, the Norse god of thunder and the Marvel superhero, has special powers when it comes to cancer too.

Researchers track muscle stem cell dynamics in response to injury and aging

December 14, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) describes the biology behind why muscle stem cells respond differently to aging or injury. The findings, published in Cell Stem Cell, ...

'Human chronobiome' study informs timing of drug delivery, precision medicine approaches

December 13, 2017
Symptoms and efficacy of medications—and indeed, many aspects of the human body itself—vary by time of day. Physicians tell patients to take their statins at bedtime because the related liver enzymes are more active during ...

Estrogen discovery could shed new light on fertility problems

December 12, 2017
Estrogen produced in the brain is necessary for ovulation in monkeys, according to researchers at the University of Wisconsin-Madison who have upended the traditional understanding of the hormonal cascade that leads to release ...

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

3-D printed microfibers could provide structure for artificially grown body parts

December 12, 2017
Much as a frame provides structural support for a house and the chassis provides strength and shape for a car, a team of Penn State engineers believe they have a way to create the structural framework for growing living tissue ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.